tiprankstipranks
Trending News
More News >
Bliss Gvs Pharma Limited (IN:BLISSGVS)
:BLISSGVS
India Market
Advertisement

Bliss Gvs Pharma Limited (BLISSGVS) Price & Analysis

Compare
2 Followers

BLISSGVS Stock Chart & Stats


BLISSGVS FAQ

What was Bliss Gvs Pharma Limited’s price range in the past 12 months?
Bliss Gvs Pharma Limited lowest stock price was ₹105.05 and its highest was ₹190.65 in the past 12 months.
    What is Bliss Gvs Pharma Limited’s market cap?
    Bliss Gvs Pharma Limited’s market cap is ₹15.32B.
      When is Bliss Gvs Pharma Limited’s upcoming earnings report date?
      Bliss Gvs Pharma Limited’s upcoming earnings report date is Oct 24, 2025 which is in 24 days.
        How were Bliss Gvs Pharma Limited’s earnings last quarter?
        Bliss Gvs Pharma Limited released its earnings results on Jul 29, 2025. The company reported ₹4.08 earnings per share for the quarter, beating the consensus estimate of N/A by ₹4.08.
          Is Bliss Gvs Pharma Limited overvalued?
          According to Wall Street analysts Bliss Gvs Pharma Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does Bliss Gvs Pharma Limited pay dividends?
            Bliss Gvs Pharma Limited pays a Annually dividend of ₹0.5 which represents an annual dividend yield of 0.34%. See more information on Bliss Gvs Pharma Limited dividends here
              What is Bliss Gvs Pharma Limited’s EPS estimate?
              Bliss Gvs Pharma Limited’s EPS estimate for its next earnings report is not yet available.
              How many shares outstanding does Bliss Gvs Pharma Limited have?
              Bliss Gvs Pharma Limited has 105,609,520 shares outstanding.
                What happened to Bliss Gvs Pharma Limited’s price movement after its last earnings report?
                Bliss Gvs Pharma Limited reported an EPS of ₹4.08 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.355%.
                  Which hedge fund is a major shareholder of Bliss Gvs Pharma Limited?
                  Currently, no hedge funds are holding shares in IN:BLISSGVS

                  Company Description

                  Bliss Gvs Pharma Limited

                  Bliss GVS Pharma Limited (BLISSGVS) is an Indian pharmaceutical company that specializes in the manufacturing and distribution of a wide range of pharmaceutical formulations. The company operates in the healthcare sector, focusing primarily on generic medicines and over-the-counter products. Bliss GVS Pharma is known for its innovative drug delivery systems and has a significant presence in both domestic and international markets.

                  Bliss Gvs Pharma Limited (BLISSGVS) Earnings & Revenues

                  BLISSGVS Stock 12 Month Forecast

                  Average Price Target

                  ₹167.00
                  ▲(15.09% Upside)
                  {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"116":"₹116","177":"₹177","131.25":"₹131.3","146.5":"₹146.5","161.75":"₹161.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":167,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹167.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":167,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹167.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":167,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹167.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[116,131.25,146.5,161.75,177],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,155.15,156.06153846153848,156.97307692307692,157.8846153846154,158.79615384615386,159.7076923076923,160.61923076923077,161.53076923076924,162.4423076923077,163.35384615384615,164.26538461538462,165.1769230769231,166.08846153846153,{"y":167,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,155.15,156.06153846153848,156.97307692307692,157.8846153846154,158.79615384615386,159.7076923076923,160.61923076923077,161.53076923076924,162.4423076923077,163.35384615384615,164.26538461538462,165.1769230769231,166.08846153846153,{"y":167,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,155.15,156.06153846153848,156.97307692307692,157.8846153846154,158.79615384615386,159.7076923076923,160.61923076923077,161.53076923076924,162.4423076923077,163.35384615384615,164.26538461538462,165.1769230769231,166.08846153846153,{"y":167,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":117.82,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":121.11,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":132.92,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":123.01,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":167.56,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":176.98,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":148.87,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":124.25,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":118.87,"date":1743465600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":118.62,"date":1746057600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":133.37,"date":1748736000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":155.15,"date":1751328000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":155.15,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Bajaj Healthcare Ltd
                  Hester Biosciences Limited
                  Jagsonpal Pharmaceuticals Ltd.
                  Syncom Formulation (India) Ltd.
                  Windlas Biotech Ltd.
                  Popular Stocks
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis